References
- Hirsch MS, Conway B, D’Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283: 2417–26.
- EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management – recommendations for the European Setting. AIDS 2001; 15: 309–20.
- Centers for Disease Control. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. 4 February 2001. Update: http://www.hivatis.org
- Taylor GP, Low-Beer N. Antiretroviral therapy in pregnancy: a focus on safety. Drug Safety 2001; 24: 683–6702.
- Garcia PM, Beckerman K, Watts H, Fox H, Rodriguez E, Tilson H, Helder J, Antiretroviral Pregnancy Registry Steering Committee. Assessing the teratogenic potential of antiretroviral drugs: data from the Antiretroviral Pregnancy Registry. 41st Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 16–19 December 2001. Abstract 1325.
- De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162: 355–6.
- Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16: 299–300.
- Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine forperinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999; 353: 773–80.
- Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomised trial. Lancet 1999; 353: 781–5.
- Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353: 786–92.
- Gray G. The PETRA study: early and late efficacy of three short AZT/3TC combination regimens to prevent mother-to-child transmission of HIV-1. XIII International AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstract LbOr5.
- Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose NVP compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795–802.
- Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading or resistance mutations in women and infants receiving NVP to prevent HIV- 1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951–7.
- Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, et al., for the Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine–zidovudine combination for prevention of maternal–infant transmission of HIV-1. JAMA 2001; 285: 2083–93.
- World Health Organization, Scaling-up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. WHO Library, 2002 June.